High rate of minimal residual disease responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)

Detalles Bibliográficos
Autores principales: Mauro, Francesca R., Molica, Stefano, Soddu, Stefano, Ilariucci, Fiorella, Coscia, Marta, Zaja, Francesco, Angelucci, Emanuele, Re, Francesca, Liberati, Anna Marina, Tedeschi, Alessandra, Reda, Gianluigi, Pietrasanta, Daniela, Gozzetti, Alessandro, Battistini, Roberta, Del Poeta, Giovanni, Musolino, Caterina, Nanni, Mauro, Piciocchi, Alfonso, Vignetti, Marco, Neri, Antonino, Albano, Francesco, Cuneo, Antonio, Del Giudice, Ilaria, Starza, Irene Della, De Propris, Maria Stefania, Raponi, Sara, Guarini, Anna R, Foà, Robin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604632/
https://www.ncbi.nlm.nih.gov/pubmed/33131259
http://dx.doi.org/10.3324/haematol.2019.235705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604632/
https://www.ncbi.nlm.nih.gov/pubmed/33131259
http://dx.doi.org/10.3324/haematol.2019.235705

Ejemplares similares